Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 552,080
  • Shares Outstanding, K 83,270
  • Annual Sales, $ 170 K
  • Annual Income, $ -23,300 K
  • 36-Month Beta 2.62
  • Price/Sales 3,075.77
  • Price/Cash Flow 0.00
  • Price/Book 3.04

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.74 +15.51%
on 05/31/17
7.03 -5.69%
on 05/24/17
-0.34 (-4.88%)
since 05/23/17
3-Month
5.74 +15.51%
on 05/31/17
8.51 -22.09%
on 03/24/17
-1.76 (-20.98%)
since 03/23/17
52-Week
1.74 +281.03%
on 08/15/16
10.54 -37.10%
on 03/13/17
+3.97 (+149.25%)
since 06/23/16

Most Recent Stories

More News
Aurinia Announces Results of Annual General Meeting

Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (NASDAQ: AUPH / TSX: AUP) is pleased to announce that the six incumbent directors of the Company were elected at the Company's annual...

AUP.TO : 8.79 (+3.66%)
AUPH : 6.63 (+3.76%)
Aurinia to Host Annual General Meeting of Shareholders and Webcast on June 21 in Vancouver, BC

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") today announced that the Company will be hosting its Annual General Meeting of Shareholders at 9 a.m. (Pacific...

AUP.TO : 8.79 (+3.66%)
AUPH : 6.63 (+3.76%)
Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?

Investors in Aurinia Pharmaceuticals Inc. (AUPH) need to pay close attention to the stock based on moves in the options market lately.

AUPH : 6.63 (+3.76%)
Voclosporin Remission Data from the Phase IIb AURA-LV Study Highlighted at EULAR 2017

---Data presented during late-breaking session

AUP.TO : 8.79 (+3.66%)
AUPH : 6.63 (+3.76%)
Technical Snapshots for These Biotech Stocks -- Gilead Sciences, Aurinia Pharma, Esperion Therapeutics, and Alexion Pharma

DailyStockTracker.com has issued research reports on Gilead Sciences Inc. (NASDAQ: GILD), Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), Esperion Therapeutics Inc. (NASDAQ: ESPR), and Alexion Pharmaceuticals...

ESPR : 44.34 (+4.80%)
AUPH : 6.63 (+3.76%)
GILD : 70.52 (+0.06%)
ALXN : 126.07 (-0.13%)
Aurinia Presents Additional Data from Phase IIB AURA-LV Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP) ("Aurinia" or the "Company") a clinical stage biopharmaceutical company focused on the global immunology market, presented additional data...

AUP.TO : 8.79 (+3.66%)
AUPH : 6.63 (+3.76%)
Aurinia to Participate in Late Breaking Oral Presentations at Two Upcoming Scientific Conferences

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that is has been selected to present...

AUP.TO : 8.79 (+3.66%)
AUPH : 6.63 (+3.76%)
Lupus Nephritis Market Global Industry Trends, Share, Size, Growth and 2030 Forecasts Report - MarketReportsOnline

PUNE, India, May 22, 2017 /PRNewswire/ --

AUPH : 6.63 (+3.76%)
RHHBY : 32.7600 (+1.42%)
GSK : 44.29 (+0.29%)
BMY : 56.64 (-1.20%)
Lupus Nephritis Market Global Industry Trends, Share, Size, Growth and 2030 Forecasts Report - MarketReportsOnline

The report "Global Lupus Nephritis Market: Industry Analysis & Outlook (2021-2030)" analyses the development of this market, with focus on the U.S, Europe and Japan markets. The major trends, growth drivers...

AUPH : 6.63 (+3.76%)
RHHBY : 32.7600 (+1.42%)
GSK : 44.29 (+0.29%)
BMY : 56.64 (-1.20%)
Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.

AUPH : 6.63 (+3.76%)
CDTX : 6.70 (-2.90%)
EDIT : 17.95 (+2.34%)
PRGO : 75.28 (+0.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Support & Resistance

2nd Resistance Point 6.92
1st Resistance Point 6.77
Last Price 6.63
1st Support Level 6.39
2nd Support Level 6.16

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.